Added to YB: 2026-04-06
Pitch date: 2026-04-01
RX.V [neutral]
BioSyent Inc.
-5.15%
current return
Author Info
Your fast track to micro-cap and small-cap earnings (under $2B Market Cap) insights. Get the key quarterly highlights for US and Canadian micro-cap and small-cap companies, without sifting through hundreds of press releases. Sign up for the newsletter.
Company Info
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
Market Cap
CAD 165.8M
Pitch Price
CAD 14.76
Price Target
N/A
Dividend
1.53%
EV/EBITDA
11.47
P/E
18.42
EV/Sales
3.21
Sector
Pharmaceuticals
Category
growth
BioSyent Inc. (TSXV:RX)
RX.V (earnings): FY25 rev $43.1M (+23% YoY), EBITDA $12.1M (+30% YoY, 28% margin), EPS $0.78 (+27%). Acquired Oral Science for $25.5M (6.33x EBITDA), adding >$30M rev & >$4M EBITDA—pro-forma combined >$70M rev, >$15.75M EBITDA. FeraMAX +12%, Tibella +32%, intl sales +302%. Raised div 10%, NCIB active, $31.9M cash pre-deal.
Read full article (2 min)